Google+ Facebook Twitter Twitter

Liquid biopsy and mathematical modelling

An evolutionary model utilising serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalised waiting time for progression.

The claim comes in a paper in Cancer Discovery – a journal of the American Association for Cancer Research.

Study author Andrea Sottoriva said: “By combining frequent longitudinal sampling of cell-free DNA with mathematical modelling of tumour evolution, we were able to make statistical predictions of patients who were at risk of progression.

“We could also determine when a cancer was going to come back, on a patient-by-patient basis. This is the first time that quantitative forecasting of this sort has been successfully used in cancer.”

The model utilising CEA measurements was applied to six patients to predict time to clinical progression. Of these predictions, three were within 10% of progression time as measured by RECIST.

Predictions generated with high sensitivity cfDNA profiling allowed for the prediction of progression time several weeks in advance, compared with models utilising CEA.

Information garnered from the cfDNA, can be used to generate multiple models based on the predicted growth of individual subclones driven by different mutations.

Image credit | Science Photo Library 

Related Articles

How to Test Tube iStock

How to…ensure correct calibration

Specialist Biomedical Scientist Dan Kelly looks into linear calibration curves, Beer-Lambert’s law and IQC interpretation.


Blood sample analysis

Nightingale Health will analyse the biomarker profiles of 500,000 blood samples from UK Biobank. 

Markers Biomarker Protein in Ovarian Cancer Sciencephoto

Clinical chemistry classics: tumour markers

This series continues with a brief review of pioneering work in the development, analysis and clinical application of important tumour markers, with two examples from the CA serum series – CA125 and CA15-3.